Specialty pharmaceutical company Aclaris Therapeutics raises $21m in a Series A round led by Vivo Ventures.
Vivo Ventures, a life-sciences focused venture capital firm, has invested in the $21m A round of Aclaris Therapeutics Inc, a US based developer of dermatological therapeutics. Fidelity Biosciences, a division of Fidelity Investments co-led the round with Vivo. The round also saw participation from Sofinnova Ventures, an independent venture capital firm with $1.4bn capital under management.
Aclaris was started by the founders of Vicept Therapeutics. Vicept was acquired by Allergen, a Botox manufacturer for $75m in cash initially and up…
